Read by QxMD icon Read

HIV Medicine

J Macías, P Monge, M Mancebo, N Merchante, K Neukam, L M Real, J A Pineda
OBJECTIVES: The aim of the study was to analyse the frequency and degree of potential drug-drug interactions (DDIs) between direct-acting antivirals (DAAs) and concomitant medication used by HIV/hepatitis C virus (HCV)-coinfected patients, including antiretroviral therapy (ART) and other drugs. METHODS: All patients with HIV infection and viraemic HCV genotype 1, 3 or 4 coinfection attending a tertiary care centre in Spain (November 2014 to November 2015) were included in the study...
November 24, 2016: HIV Medicine
C L Townsend, A de Ruiter, H Peters, C Nelson-Piercy, P Tookey, C Thorne
OBJECTIVES: The aim of the study was to compare maternal characteristics and pregnancy outcomes in women aged < 40 years and ≥ 40 years in a large unselected population of HIV-positive women delivering in the UK and Ireland between 2000 and 2014. METHODS: Comprehensive population-based surveillance data on all HIV-positive pregnant women and their children seen for care in the UK and Ireland are collected through the National Study of HIV in Pregnancy and Childhood...
November 16, 2016: HIV Medicine
A R Webel, A Sattar, N T Funderburg, B Kinley, C T Longenecker, D Labbato, Sm Khurshid Alam, G A McComsey
OBJECTIVES: HIV-infected adults have heightened monocyte activation and inflammation, at least partially as a consequence of altered gut integrity. The role of dietary factors in microbial translocation and inflammation and their downstream effect on markers of cardiovascular disease (CVD) have not been explored. Our purpose was to describe the longitudinal dietary patterns of HIV-infected adults, and to examine the relationship between dietary intake, gut integrity, inflammation and subclinical markers of CVD in HIV-infected adults...
November 9, 2016: HIV Medicine
J Underwood, D De Francesco, F A Post, J H Vera, I Williams, M Boffito, P W Mallon, J Anderson, M Sachikonye, C Sabin, A Winston
OBJECTIVES: While cognitive impairment is frequently reported in HIV-positive individuals and has historically been associated with poorer functional outcomes, the associations between cognitive impairment and patient-reported outcome measures (PROMs) in contemporary cohorts are unclear. METHODS: We tested cognitive function using a computerized battery (CogState(™) ) in 290 HIV-positive and 97 HIV-negative individuals aged ≥ 50 years participating in the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study...
October 26, 2016: HIV Medicine
D Grint, E Tedaldi, L Peters, A Mocroft, B Edlin, S Gallien, H Klinker, C Boesecke, P Kokordelis, J K Rockstroh
OBJECTIVES: Studies have shown that hepatitis C virus (HCV) RNA levels remain stable over time in HIV/HCV-coinfected individuals taking combination antiretroviral therapy (cART), while spontaneous clearance of HCV RNA during the persistent infection phase has been documented only rarely among those with the CC interleukin (IL)-28B genotype. This study describes HCV RNA profiles and factors associated with changes over time in HCV RNA levels in the ESPRIT study. METHODS: HIV/HCV-coinfected individuals positive for HCV RNA were included in the study...
October 26, 2016: HIV Medicine
G Ferraioli
No abstract text is available yet for this article.
October 4, 2016: HIV Medicine
M St-Jean, P R Harrigan, P Sereda, Jsg Montaner, V D Lima
OBJECTIVES: The World Health Organization (WHO)'s HIV drug resistance (HIVDR) early warning indicators (EWIs) measure antiretroviral therapy (ART)-site factors associated with HIVDR prevention, without HIVDR laboratory testing. We assessed the relationship between EWIs and HIVDR acquisition using data from British Columbia, Canada. METHODS: Eligible patients were ART-naïve, were ≥ 19 years old, had initiated ART between 1 January 2000 and 31 December 2012, had ≥ 15 months of follow-up, and were without transmitted HIVDR...
October 4, 2016: HIV Medicine
C E Canan, B Lau, M E McCaul, J Keruly, R D Moore, G Chander
OBJECTIVES: The aim of the study was to examine the association between levels of past and current alcohol consumption and all-cause and liver-related mortality among people living with HIV (PLWH). METHODS: A prospective cohort study of 1855 PLWH in Baltimore, MD was carried out from 2000 to 2013. We ascertained alcohol use by (1) self-report (SR) through a computer-assisted self interview, and (2) medical record abstraction of provider-documented (PD) alcohol use...
September 28, 2016: HIV Medicine
C Y Leng, H C Low, L L Chua, M L Chong, H Sulaiman, I Azwa, J M Roberts, A Kamarulzaman, R Rajasuriar, Y L Woo
OBJECTIVES: Human papillomavirus (HPV)-associated cancers disproportionately affect those infected with HIV despite effective combination antiretroviral therapy (cART). The primary aim of this study was to quantify HPV16 and HPV52 E6-specific interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) T-cell responses, a correlate of protective immunity, in the first year following cART initiation and subsequently in those patients with suboptimal (sIR) and optimal (oIR) immune reconstitution...
September 20, 2016: HIV Medicine
P Feuillet, F Lert, L Tron, C Aubriere, B Spire, R Dray-Spira
OBJECTIVES: Depression is common among people living with HIV (PLWHIV) and is associated with poorer therapeutic outcomes and risky behaviours. We sought to estimate the prevalence of major depressive episode (MDE) across PLWHIV groups, to compare this with its prevalence in the general population and to assess factors associated with it. METHODS: We used data from the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-Vespa2 study, a national study on a representative sample of PLWHIV conducted in France in 2011...
September 14, 2016: HIV Medicine
A Judd, R Lodwick, A Noguera-Julian, D M Gibb, K Butler, D Costagliola, C Sabin, A van Sighem, B Ledergerber, C Torti, A Mocroft, D Podzamczer, M Dorrucci, S De Wit, N Obel, F Dabis, A Cozzi-Lepri, F García, N H Brockmeyer, J Warszawski, M I Gonzalez-Tome, C Mussini, G Touloumi, R Zangerle, J Ghosn, A Castagna, G Fätkenheuer, C Stephan, L Meyer, M A Campbell, G Chene, A Phillips
OBJECTIVES: The aim of the study was to determine the time to, and risk factors for, triple-class virological failure (TCVF) across age groups for children and adolescents with perinatally acquired HIV infection and older adolescents and adults with heterosexually acquired HIV infection. METHODS: We analysed individual patient data from cohorts in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). A total of 5972 participants starting antiretroviral therapy (ART) from 1998, aged < 20 years at the start of ART for those with perinatal infection and 15-29 years for those with heterosexual infection, with ART containing at least two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (bPI), were followed from ART initiation until the most recent viral load (VL) measurement...
September 14, 2016: HIV Medicine
F Zhong, W Tang, W Cheng, P Lin, Q Wu, Y Cai, S Tang, L Fan, Y Zhao, X Chen, J Mao, G Meng, J D Tucker, H Xu
OBJECTIVES: HIV self-testing (HIVST) offers an opportunity to increase HIV testing among people not reached by facility-based services. However, the promotion of HIVST is limited as a consequence of insufficient community engagement. We built a social entrepreneurship testing (SET) model to promote HIVST linkage to care among Chinese men who have sex with men (MSM) in Guangzhou. METHODS: The SET model includes a few key steps. Each participant first completed an online survey, and paid a US$23 (refundable) deposit to receive an HIVST kit and a syphilis self-testing (SST) kit...
September 7, 2016: HIV Medicine
M Noy, E E Merika, N Morar, M Nelson, L C Fuller
No abstract text is available yet for this article.
January 2017: HIV Medicine
S Madge, C Smith, C Warren-Gash, J Bayly, A Bartley
No abstract text is available yet for this article.
January 2017: HIV Medicine
C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf, H-J Stellbrink, C Wyen
OBJECTIVES: Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is now among the most frequently used antiretroviral agents. However, recent reports have raised concerns about potential neurotoxicity. METHODS: We performed a retrospective analysis of a cohort of HIV-infected patients who had initiated an INSTI in two large German out-patient clinics between 2007 and 2016. We compared discontinuation rates because of adverse events (AEs) within 2 years of starting treatment with dolutegravir, raltegravir or elvitegravir/cobicistat...
January 2017: HIV Medicine
V Bouteloup, C Sabin, A Mocroft, L Gras, N Pantazis, V Le Moing, A d'Arminio Monforte, M Mary-Krause, B Roca, J M Miro, M Battegay, N Brockmeyer, J Berenguer, P Morlat, N Obel, S De Wit, G Fätkenheuer, R Zangerle, J Ghosn, S Pérez-Hoyos, M Campbell, M Prins, G Chêne, L Meyer, M Dorrucci, C Torti, R Thiébaut
OBJECTIVES: The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. METHODS: All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged ≥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load ≤ 50 HIV-1 RNA copies/mL at 6 months (± 3 months) after cART initiation were included in the study...
January 2017: HIV Medicine
D Armenia, D Di Carlo, G Maffongelli, V Borghi, C Alteri, F Forbici, A Bertoli, C Gori, M Giuliani, E Nicastri, M Zaccarelli, C Pinnetti, S Cicalini, G D'Offizi, F Ceccherini-Silberstein, C Mussini, A Antinori, M Andreoni, C F Perno, M M Santoro
OBJECTIVES: We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. METHODS: Data from 206 drug-naïve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses...
January 2017: HIV Medicine
M Li, Y Foli, Z Liu, G Wang, Y Hu, Q Lu, S Selvaraj, W Lam, E Paintsil
OBJECTIVES: We recently observed a decrease in deoxyribonucleotide (dNTP) pools in HIV-infected individuals on antiretroviral therapy (ART). Alterations in dNTPs result in mutations in mitochondrial DNA (mtDNA) in cell culture and animal models. Therefore, we investigated whether ART is associated with mitochondrial genome sequence variation in peripheral blood mononuclear cells (PBMCs) of HIV-infected treatment-experienced individuals. METHODS: In this substudy of a case-control study, 71 participants were included: 22 'cases', who were HIV-infected treatment-experienced patients with mitochondrial toxicity, 25 HIV-infected treatment-experienced patients without mitochondrial toxicity, and 24 HIV-uninfected controls...
January 2017: HIV Medicine
P M Girard, A Antinori, J R Arribas, D Ripamonti, C Bicer, B Netzle-Sveine, B Hadacek, C Moecklinghoff
OBJECTIVES: PROTEA is a randomized controlled trial to assess the efficacy and safety of darunavir/ritonavir (DRV/r) monotherapy as an alternative to triple therapy. METHODS: Patients fully suppressed on first-line antiretrovirals (viral load < 50 HIV-1 RNA copies/mL) were switched to DRV/r 800/100 mg once daily, either as monotherapy (n = 137) or with two nucleoside reverse transcriptase inhibitors (NRTIs) (n = 136). Treatment failure was HIV-1 RNA level ≥ 50 copies/mL at week 96 or discontinuation of study treatment [Food and Drug Administration (FDA) snapshot algorithm]...
January 2017: HIV Medicine
L Tugume, B M Morawski, M Abassi, N C Bahr, R Kiggundu, H W Nabeta, K H Hullsiek, K Taseera, A K Musubire, C Schutz, C Muzoora, D A Williams, M A Rolfes, G Meintjes, J Rhein, D B Meya, D R Boulware
OBJECTIVES: Anaemia represents a common toxicity with amphotericin B-based induction therapy in HIV-infected persons with cryptococcal meningitis. We sought to examine the impact of amphotericin-related anaemia on survival. METHODS: We used data from Ugandan and South African trial participants to characterize the variation of haemoglobin concentrations from diagnosis to 12 weeks post-diagnosis. Anaemia severity was classified based on the haemoglobin concentration at cryptococcal meningitis diagnosis, and nadir haemoglobin values during amphotericin induction...
January 2017: HIV Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"